Catalyst Wire Dossier Catalyst Wire Dossier

Fremanezumab (TEV-48125)

fremanezumab · Teva Branded Pharmaceutical Products R&D, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Fremanezumab (TEV-48125), covering 2019-08-28 to 2019-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine [Phase 3]

See pricing